Literature DB >> 26092699

Oligo-Recurrence of Osteosarcoma Patients: Treatment Strategies for Pulmonary Metastases.

Shintaro Iwata1, Tsukasa Yonemoto2, Toshihiko Iizasa3, Yuzuru Niibe4, Hiroto Kamoda2, Takeshi Ishii2.   

Abstract

BACKGROUND: Distant metastases from osteosarcoma most commonly occur in the lungs. Osteosarcoma can be cured by complete surgical resection of all metastatic lesions if the number is limited (oligo-recurrence: ≤ 5 metastatic or recurrent lesions with controlled primary lesions). This study aimed to clarify the prognostic factors for osteosarcoma patients with pulmonary metastasis and determine their oligo-recurrence status.
METHODS: Patients with conventional osteosarcoma who underwent definitive surgery for the primary lesion and at least one thoracotomy for pulmonary metastases were recruited to this retrospective study. Clinicopathological information was collected on each thoracotomy from 1976 to 2011, and was then analyzed statistically. We counted the number of resected nodules that were pathologically confirmed as metastatic lesions from osteosarcoma.
RESULTS: In total, 151 thoracotomies in 71 patients were analyzed. Forty-seven patients (66 %) underwent up to two thoracotomies, and the maximum number of thoracotomies was six. The median number of resected nodules on each thoracotomy was two, and the median total size of metastatic lesions was 20 mm. Incomplete surgical remission [relative risk (RR) 3.42], a less than 1-year interval from a previous thoracotomy (RR 1.97), more than three resected nodules (RR 2.42); and total size of more than 30 mm for pulmonary metastases (RR 2.19) were independent predictors of increased risk of tumor death by multivariate analysis.
CONCLUSIONS: We propose that factors contributing to oligo-recurrence of patients with pulmonary metastatic osteosarcoma include complete surgical remission, an interval from a previous thoracotomy, number of resected nodules, and total size of pulmonary metastases.

Entities:  

Mesh:

Year:  2015        PMID: 26092699     DOI: 10.1245/s10434-015-4682-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  Survival and prognostic factors following pulmonary metastasectomy for sarcoma.

Authors:  Giuseppe Marulli; Marco Mammana; Giovanni Comacchio; Federico Rea
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

2.  Details of recurrence sites after definitive radiation therapy for cervical cancer.

Authors:  Reiko Kobayashi; Hideomi Yamashita; Kae Okuma; Kuni Ohtomo; Keiichi Nakagawa
Journal:  J Gynecol Oncol       Date:  2015-10-08       Impact factor: 4.401

3.  Efficacy and safety of stereotactic radiosurgery for pulmonary metastases from osteosarcoma: Experience in 73 patients.

Authors:  Wenxi Yu; Zimei Liu; Lina Tang; Feng Lin; Yang Yao; Zan Shen
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

4.  A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma.

Authors:  James Coventon
Journal:  J Bone Oncol       Date:  2017-08-04       Impact factor: 4.072

5.  Long non-coding RNA phosphatase and tensin homolog pseudogene 1 suppresses osteosarcoma cell growth via the phosphoinositide 3-kinase/protein kinase B signaling pathway.

Authors:  Bin Yan; Aikepaer Wubuli; Yidong Liu; Xin Wang
Journal:  Exp Ther Med       Date:  2018-04-02       Impact factor: 2.447

6.  Prospero homeobox 1 promotes proliferation, migration, and invasion of osteosarcoma cells and its clinical significance.

Authors:  Dawei Liu; Ran Wang; Yuefeng Wang; Ye Wang; Liantang Wang
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

7.  [Treatment Outcomes and Prognostic Factors of Pulmonary Metastasectomy for Bone and Soft Tissue Sarcoma: a High Volume Academic Institution Experience].

Authors:  Xiaozheng Kang; Wanpu Yan; Yongbo Yang; Liang Dai; Zhen Liang; Zhen Huang; Xiaohui Niu; Keneng Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.